Status:
UNKNOWN
Benefits of GIK in Cardiac Surgery Patients
Lead Sponsor:
Xijing Hospital
Conditions:
Cardiac Surgery
Cardiopulmonary Bypass
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the effects of modified glucose - insulin - potassium (GIK) therapy in cardiac surgery patients undergoing cardiopulmonary bypass (CPB).
Detailed Description
Cardiopulmonary bypass (CPB) is a necessary technique to maintain the circulation during cardiac surgery. But CPB itself is associated with a series of problems of organs, such as hyperglycemia induce...
Eligibility Criteria
Inclusion
- Between 18 and 70 years of age
- Elective cardiac surgery with first time cardiopulmonary bypass
- Left ventricular ejection fraction(LVEF) ≥ 30%
- Informed agreement signed
Exclusion
- Previous cardiac surgery
- Emergent surgery
- Cardiac surgery without the use of cardiopulmonary bypass
- Diabetes mellitus
- Severe renal insufficiency
- Severe respiratory insufficiency
- Serious preoperative illness (sepsis, active infection or active malignancy requiring treatment)
- Pregnant woman or positive pregnancy test
- History of drug abuse
- Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion
- Enrollment in another clinical study
- Lack of informed consent
Key Trial Info
Start Date :
February 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2022
Estimated Enrollment :
930 Patients enrolled
Trial Details
Trial ID
NCT01516138
Start Date
February 1 2012
End Date
February 1 2022
Last Update
October 31 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Deparment of Cardiovascular surgery,Xijing Hospital, Fourth Military Medical University
Xi'an, Shaanxi, China, 710032